Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEMUS: Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
NCT07319429Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, medroxyprogesterone acetate, megestrol, triptorelin, letrozole in endometrial cancer (EC), sponsored by Fudan University. Started Jan 2026; status: recruiting.
02
Drugs
sintilimabmedroxyprogesterone acetatemegestroltriptorelinletrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07319429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319429.